Disintegrin Rhodostomin Mutant Ameliorates the Severity of Experimental Proliferative Vitreoretinopathy by Suppressing Both Integrin αvβ3 and α5β1
The FASEB Journal · 2025
DOI: 10.1096/fj.202402498rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Yu-Chien Tsao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Integrin alphaVbeta3, Vitreoretinopathy, Proliferative, Integrin alpha5beta1, Disintegrins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Ministry of Science and Technology (MOST).
Abstract (Originalsprache)
Proliferative vitreoretinopathy (PVR) is a severe complication after rhegmatogenous retinal detachment (RD) surgery and needs further surgical treatments. So far there are no effective drugs for prevention and treatment of PVR. Both integrins αvβ3 and α5β1 are related to human PVR formation. Disintegrins are antagonists of integrins. The drug, a mutant of snake venom‐derived disintegrin, also called disintegrin Rhodostomin (Rho) mutant, is a potent antagonist of both integrins αvβ3 and α5β1, of which the effect on PVR remains poorly understood. In vitro assays were used to assess the effects of disintegrin Rho mutant treatment on the proliferation, migration, and adhesion of the retinal pigment epithelial (RPE) cell line derived from human, ARPE‐19. In vivo, mice with PVR induction were treated with disintegrin Rho mutant and monitored for PVR severity. In vitro results showed that disintegrin Rho mutant reduced the migration, proliferation, and adhesion of ARPE‐19 cells. In vivo results revealed that it could significantly ameliorate the severity of PVR and suppress expression of both integrin αvβ3 and α5β1 and epithelial‐mesenchymal transition (EMT) in mouse eyes. Besides, we found decreases in Akt, STAT3, and ERK activation by disintegrin Rho mutant both in vitro and in vivo. In conclusion, disintegrin Rho mutant mitigates experimental PVR with reduced expression of both integrin αvβ3 and α5β1 and presents a potential therapeutic option for PVR in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Ophthalmology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
ORCID-Profile: Yu-Chien Tsao, Chang-Hao Yang, Sheng-Min Hsu
Förderung
- Ministry of Science and Technology (MOST)
Zitieren
APA
Tsao, Y. C., Chen, S. H., Ou, Y. C., Chuang, W. J., Yang, C. H., Lin, C. J., & Hsu, S. M. (2025). Disintegrin Rhodostomin Mutant Ameliorates the Severity of Experimental Proliferative Vitreoretinopathy by Suppressing Both Integrin αvβ3 and α5β1. The FASEB Journal. https://doi.org/10.1096/fj.202402498rr
Vancouver
Tsao YC, Chen SH, Ou YC, Chuang WJ, Yang CH, Lin CJ, et al. Disintegrin Rhodostomin Mutant Ameliorates the Severity of Experimental Proliferative Vitreoretinopathy by Suppressing Both Integrin αvβ3 and α5β1. The FASEB Journal. 2025. doi:10.1096/fj.202402498rr
BibTeX
@article{Tsao2025,
author = {Tsao, Yu-Chien and Chen, Shun-Hua and Ou, Yi-Chun and Chuang, Woei-Jer and Yang, Chang-Hao and Lin, Chia-Jhen and Hsu, Sheng-Min},
title = {Disintegrin Rhodostomin Mutant Ameliorates the Severity of Experimental Proliferative Vitreoretinopathy by Suppressing Both Integrin αvβ3 and α5β1},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202402498rr}
}
EUVIMED